Prognostic Value of Serum Soluble Klotho and Fibroblast Growth Factor-23 in Multiple Myeloma Patients.
Fibroblast growth factor (FGF)-23
Klotho
Multiple myeloma
Survival outcomes
Journal
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
ISSN: 0971-4502
Titre abrégé: Indian J Hematol Blood Transfus
Pays: India
ID NLM: 9425818
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
17
09
2020
accepted:
05
07
2021
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
ppublish
Résumé
Multiple myeloma is the plasma cell malignancy in which bone involvement is common. The Fibroblast growth factor-23 (FGF-23)/Klotho pathway plays a major role in mineral metabolism that FGF-23 is mineralization inhibitory. Klotho also has anti-apoptotic and anti-tumor effects by acting as a tumor suppressor gene. There is a negative correlation between serum FGF-23 and serum soluble Klotho (sKL) levels. As such, there can be considerable interest in investigating sKL and FGF-23 as a biomarker in patients with MM. We used an enzyme-linked immunosorbent assay to measure serum FGF-23 and sKL levels in 55 newly diagnosed MM patients and 23 healthy controls. We determined significantly high serum FGF-23 and low serum sKL levels in MM patients when compared to healthy controls. Serum sKL levels correlated negatively with a p53 positive mutation status, with high ISS, elevated lactate dehydrogenase, C-reactive protein, Beta-2 microglobulin levels. Serum FGF-23 levels are associated negatively with serum phosphorus and positively only light chains and p53 mutation. Patients with high serum FGF-23 levels had significantly shorter median overall survival than those with low serum FGF-23 levels (
Identifiants
pubmed: 35747582
doi: 10.1007/s12288-021-01470-5
pii: 1470
pmc: PMC9209547
doi:
Types de publication
Journal Article
Langues
eng
Pagination
454-463Informations de copyright
© Indian Society of Hematology and Blood Transfusion 2021.
Déclaration de conflit d'intérêts
Conflict of ınterestThe authors report no declarations of interest.
Références
Biomed Res Int. 2018 Aug 12;2018:9481475
pubmed: 30159331
J Clin Oncol. 2005 May 20;23(15):3412-20
pubmed: 15809451
J Hematol Oncol. 2017 Feb 2;10(1):37
pubmed: 28153033
Endocr Rev. 2015 Apr;36(2):174-93
pubmed: 25695404
Oncol Rep. 2017 Aug;38(2):967-974
pubmed: 28656297
Kidney Dis (Basel). 2017 Jul;3(1):15-23
pubmed: 28785560
FEBS Lett. 1998 Mar 6;424(1-2):6-10
pubmed: 9537505
J Cell Biochem. 2010 Feb 1;109(2):283-91
pubmed: 20014067
Bone. 2006 Aug;39(2):369-76
pubmed: 16644301
Horm Mol Biol Clin Investig. 2016 Oct 1;28(1):55-67
pubmed: 26943611
Hum Pathol. 2013 May;44(5):795-801
pubmed: 23123137
Bone. 2017 Jul;100:62-68
pubmed: 27622885
Curr Opin Nephrol Hypertens. 2018 Jul;27(4):229-235
pubmed: 29851418
Curr Opin Nephrol Hypertens. 2018 Jul;27(4):298-304
pubmed: 29697410
Cancer. 2007 Oct 15;110(8):1860-7
pubmed: 17763372
Front Endocrinol (Lausanne). 2018 Aug 07;9:436
pubmed: 30131767
Am J Hematol. 2018 Aug 16;93(8):981-1114
pubmed: 30400719
Clin Exp Nephrol. 2012 Oct;16(5):722-9
pubmed: 22457086
Int J Nephrol. 2018 May 21;2018:9679841
pubmed: 29951315
Lung Cancer. 2011 Jun;72(3):355-9
pubmed: 21075474
Leukemia. 2009 Jan;23(1):3-9
pubmed: 18971951
Br J Haematol. 2003 Jun;121(5):749-57
pubmed: 12780789
Int J Mol Sci. 2019 Feb 06;20(3):
pubmed: 30736285
J Clin Oncol. 2013 Jun 20;31(18):2347-57
pubmed: 23690408
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Front Endocrinol (Lausanne). 2017 Nov 17;8:323
pubmed: 29250031
Iran J Basic Med Sci. 2018 Jan;21(1):3-8
pubmed: 29372030
Oncotarget. 2015 Aug 14;6(23):19647-60
pubmed: 25944690
Biochem Biophys Res Commun. 2010 Jul 30;398(3):513-8
pubmed: 20599764
Biochem Biophys Res Commun. 1998 Jan 26;242(3):626-30
pubmed: 9464267
Adv Drug Deliv Rev. 2017 Nov 1;121:85-100
pubmed: 28709936
Biochem Biophys Res Commun. 2015 Nov 27;467(4):1019-25
pubmed: 26462468
Endocr Relat Cancer. 2011 Jun 08;18(3):R53-77
pubmed: 21490240